Wednesday: What AI is actually changing in biopharma

Wednesday, Oct. 14, 2026 | Virtual | 11 am ET

AI has already changed biopharma. The first AI-designed drugs are in the clinic and record money keeps coming in. What hasn't been settled is where it pays off, and for whom.

That's the question on Wednesday. Endpoints News Senior Biopharma Correspondent Andrew Dunn spends the day with the researchers, executives and investors working it out: What changes for the people building the future of medicine?

In-person spots are sold out. Join us online for our free virtual program, plus livestreams of select afternoon sessions.

GET YOUR VIRTUAL PASS

Virtual agenda highlights:

Exclusive conversations with Nobel laureate David Baker and Anthropic's Nathan Frey*
How to build biological intelligence without destroying us all, with Radical Numerics*
The future of work at pharma giants, with Bristol Myers, Takeda and Bayer*
What AI does to human skills, with OpenEvidence, UCI Health and Harvard Medical School

*Livestreamed from New York.

Eric Nguyen
Co-Founder & CEO
Radical Numerics

David Baker
Professor, Biochemistry; Director, Institute for Protein Design
University of Washington - HHMI Investigator

Nathan Frey
Head of Drug Discovery & Development Research
Anthropic

Sydney Klein
SVP, Chief Information Security Officer & Head of Enterprise IT
Bristol Myers Squibb

The virtual program is free and starts at 11 am ET on Wednesday. Join us.

GET YOUR FREE VIRTUAL PASS